{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:13Z","timestamp":1793414113146,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01194-8","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:42:51Z","timestamp":1765996971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quantifying the Full-to-Empty Adeno-Associated Virus (AAV) Capsid Ratios and Their Impact on Transduction Efficiency in vitro"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3013-2673","authenticated-orcid":false,"given":"Brandon","family":"Hoyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5111-3809","authenticated-orcid":false,"given":"Jonathan","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-5651","authenticated-orcid":false,"given":"Dhimiter","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","volume":"1","author":"R Samulski","year":"2014","unstructured":"Samulski R, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1:427\u201351. https:\/\/doi.org\/10.1146\/annurev-virology-031413-085355.","journal-title":"Annu Rev Virol"},{"key":"1194_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41434-024-00477-7","volume":"31","author":"M Cui","year":"2024","unstructured":"Cui M, Su Q, Yip M, McGowan J, Punzo C, Gao G, et al. The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2. Gene Ther. 2024;31:489\u201398. https:\/\/doi.org\/10.1038\/s41434-024-00477-7.","journal-title":"Gene Ther"},{"issue":"12","key":"1194_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","volume":"27","author":"A Rashnonejad","year":"2019","unstructured":"Rashnonejad A, Chermahini G, Gunduz C, Onay H, Aykut A, Durmaz B, et al. Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice. Mol Ther. 2019;27(12):2123\u201333. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.017.","journal-title":"Mol Ther"},{"key":"1194_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2021.107764","volume":"49","author":"S Sha","year":"2021","unstructured":"Sha S, Maloney A, Katsikis G, Nguyen T, Neufeld C, Wolfrum J, et al. Cellular pathways of recombinant adeno-associated virus production for gene therapy. Biotechnol Adv. 2021;49:107764. https:\/\/doi.org\/10.1016\/j.biotechadv.2021.107764.","journal-title":"Biotechnol Adv"},{"key":"1194_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.aivir.2020.01.002","volume":"106","author":"J Zengel","year":"2020","unstructured":"Zengel J, Carette J. Structural and cellular biology of adeno-associated virus attachment and entry. Adv Virus Res. 2020;106:39\u201384. https:\/\/doi.org\/10.1016\/bs.aivir.2020.01.002.","journal-title":"Adv Virus Res"},{"issue":"2","key":"1194_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du S, Davis J, Choi E, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185(2):250-265.e16. https:\/\/doi.org\/10.1016\/j.cell.2021.12.021.","journal-title":"Cell"},{"issue":"7","key":"1194_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/pathogens11070756","volume":"11","author":"J Becker","year":"2022","unstructured":"Becker J, Fakhiri J, Grimm D. Fantastic AAV gene therapy vectors and how to find them \u2013 random diversification, rational design, and machine learning. Pathogens. 2022;11(7):756. https:\/\/doi.org\/10.3390\/pathogens11070756.","journal-title":"Pathogens"},{"key":"1194_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00470-4","volume":"7","author":"G Sanyal","year":"2022","unstructured":"Sanyal G. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. NPJ Vaccines. 2022;7:50. https:\/\/doi.org\/10.1038\/s41541-022-00470-4.","journal-title":"NPJ Vaccines"},{"key":"1194_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00249-023-01661-0","volume":"52","author":"A Bepperling","year":"2023","unstructured":"Bepperling A, Best J. Comparison of three AUC techniques for the determination of the loading status and capsid titer of AAVs. Eur Biophys J. 2023;52:401\u201313. https:\/\/doi.org\/10.1007\/s00249-023-01661-0.","journal-title":"Eur Biophys J"},{"key":"1194_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.omtm.2021.04.008","volume":"21","author":"H Khasa","year":"2021","unstructured":"Khasa H, Kilby G, Chen X, Wang C. Analytical band centrifugation for the separation and quantification of empty and full AAV particles. Mol Ther Methods Clin Dev. 2021;21:585\u201391. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.008.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.omtm.2021.02.010","volume":"20","author":"A Gimpel","year":"2021","unstructured":"Gimpel A, Katsikis G, Sha S, Maloney A, Hong M, Nguyen T, et al. Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies. Mol Ther Methods Clin Dev. 2021;20:740\u201354. https:\/\/doi.org\/10.1016\/j.omtm.2021.02.010.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1194_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2339702","volume":"2023","author":"A Lam","year":"2023","unstructured":"Lam A, Mulcrone P, Frabutt D, Zhang J, Chrzanowski M, Arisa S, et al. Comprehensive comparison of AAV purification methods: iodixanol gradient centrifugation vs. immuno-affinity chromatography. Adv Cell Gene Ther. 2023;2339702. https:\/\/doi.org\/10.1155\/2023\/2339702.","journal-title":"Adv Cell Gene Ther"},{"issue":"13","key":"1194_CR13","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1021\/acs.analchem.6b00883","volume":"88","author":"E Pierson","year":"2016","unstructured":"Pierson E, Keifer D, Asokan A, Jarrold M. Resolving adeno-associated viral particle diversity with charge detection mass spectrometry. Anal Chem. 2016;88(13):6718\u201325. https:\/\/doi.org\/10.1021\/acs.analchem.6b00883.","journal-title":"Anal Chem"},{"issue":"7","key":"1194_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2174\/1566524020666200915105456","volume":"20","author":"T Li","year":"2020","unstructured":"Li T, Gao T, Chen H, Pekker P, Menyhart A, Guttman A. Rapid determination of full and empty adeno-associated virus capsid ratio by capillary isoelectric focusing. Curr Mol Med. 2020;20(7):814\u201320. https:\/\/doi.org\/10.2174\/1566524020666200915105456.","journal-title":"Curr Mol Med"},{"issue":"13","key":"1194_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311033","volume":"24","author":"C Wagner","year":"2023","unstructured":"Wagner C, Fuchsberger F, Innthaler B, Lemmerer M, Birner-Gruenberger R. Quantification of empty, partially filled and full adeno-associated virus vectors using mass photometry. Int J Mol Sci. 2023;24(13):11033. https:\/\/doi.org\/10.3390\/ijms241311033.","journal-title":"Int J Mol Sci"},{"key":"1194_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.omtm.2021.04.003","volume":"21","author":"S Khatwani","year":"2021","unstructured":"Khatwani S, Pavlova A, Pirot Z. Anion-exchange HPLC assay for separation and quantification of empty and full capsids in multiple adeno-associated virus serotypes. Mol Ther Methods Clin Dev. 2021;21:548\u201358. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1194_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124206","volume":"1242","author":"Y Lee","year":"2024","unstructured":"Lee Y, Lee J, Fang K, Gee G, Rogers B, McNally D, et al. Separation of full, empty, and partial adeno-associated virus capsids via anion-exchange chromatography with continuous recycling and accumulation. J Chromatogr B. 2024;1242:124206. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124206.","journal-title":"J Chromatogr B"},{"key":"1194_CR18","unstructured":"U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Silver Spring, MD; 2024. Available from: Approved Cellular and Gene Therapy Products | FDA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products.\u00a0Accessed 1 Aug 2024."},{"key":"1194_CR19","unstructured":"U.S. Food and Drug Administration. Potency Assurance for Cellular and Gene Therapy Products. Silver Spring, MD; 2025. Available from: Potency Assurance for Cellular and Gene Therapy Products | FDA. https:\/\/www.fda.gov\/media\/175132\/download.\u00a0Accessed 20 Jan 2025."},{"issue":"3","key":"1194_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.30574\/gscbps.2019.6.3.0034","volume":"6","author":"K Bhavyasri","year":"2019","unstructured":"Bhavyasri K, Vishnumurthy K, Rambabu D, Sumakanth M. ICH guidelines \u2013 \u201cQ\u201d series (quality guidelines) \u2013 a review. GSC Biol Pharm Sci. 2019;6(3):89\u2013106. https:\/\/doi.org\/10.30574\/gscbps.2019.6.3.0034.","journal-title":"GSC Biol Pharm Sci"},{"issue":"5","key":"1194_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jpba.2005.02.037","volume":"38","author":"S Branch","year":"2005","unstructured":"Branch S. Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal. 2005;38(5):798\u2013805. https:\/\/doi.org\/10.1016\/j.jpba.2005.02.037.","journal-title":"J Pharm Biomed Anal"},{"key":"1194_CR22","unstructured":"Analysis of Biological Assays. Available from: https:\/\/www.drugfuture.com\/Pharmacopoeia\/usp35\/PDF\/5186-5201%20%5B1034%5D%20Analysis%20of%20Biological%20Assays.pdf. Accessed 13 Apr 2025."},{"key":"1194_CR23","unstructured":"U.S. Food and Drug Administration. Q8 (R2) Pharmaceutical Development. Silver Springs, MD; 2025. Available from: Q8(R2) Pharmaceutical Development | FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q8r2-pharmaceutical-development.\u00a0Accessed 16 Jan 2025."},{"key":"1194_CR24","unstructured":"Total Pharmaceutical Topic. What does SISPQ stand for? In Pharmaceutical Industry. Available from: What does SISPQ stands for? In Pharmaceutical Industry \u2013 totalpharmaceuticaltopics.com. https:\/\/totalpharmaceuticaltopics.com\/2024\/05\/what-does-sispq-stands-for-in-pharmaceutical-industry\/. Accessed 12 Apr 2025."},{"key":"1194_CR25","unstructured":"U.S. Food and Drug Administration. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Silver Springs, MD; 2025. Available from: Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances | FDA. https:\/\/www.ema.europa.eu\/en\/ich-q6a-specifications-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical-substances-scientific-guideline. Accessed 13 Apr 2025."},{"key":"1194_CR26","unstructured":"U.S. Food and Drug Administration. Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products. Silver Springs, MD; 2025. Available from: Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products | FDA. https:\/\/www.ema.europa.eu\/en\/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products-scientific-guideline. Accessed 04\/13\/2025."},{"key":"1194_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41434-024-00444-2","volume":"31","author":"A McColl-Carboni","year":"2024","unstructured":"McColl-Carboni A, Dollive S, Laughlin S, Lushi R, MacArthur M, Zhou S, et al. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Ther. 2024;31:285-294. https:\/\/doi.org\/10.1038\/s41434-024-00444-2.","journal-title":"Gene Ther"},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/mtm.2013.9","volume":"1","author":"K Gao","year":"2014","unstructured":"Gao K, Li M, Zhong L, Su Q, Li J, Li S, et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. Mol Ther Methods Clin Dev. 2014;1:9. https:\/\/doi.org\/10.1038\/mtm.2013.9.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"1194_CR29","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/mt.2015.179","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Bell P, Somanathan S, Wang Q, He Z, Yu H, et al. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther. 2015;23(12):1877\u201387. https:\/\/doi.org\/10.1038\/mt.2015.179.","journal-title":"Mol Ther"},{"issue":"9","key":"1194_CR30","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2013.176","volume":"21","author":"B Hoffman","year":"2013","unstructured":"Hoffman B, Herzog R. Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Mol Ther. 2013;21(9):1648\u201350. https:\/\/doi.org\/10.1038\/mt.2013.176.","journal-title":"Mol Ther"},{"issue":"1","key":"1194_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mt.2013.268","volume":"22","author":"J Wright","year":"2014","unstructured":"Wright J. AAV empty capsids: for better or for worse? Mol Ther. 2014;22(1):1\u20132. https:\/\/doi.org\/10.1038\/mt.2013.268.","journal-title":"Mol Ther"},{"key":"1194_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02023-20","author":"L Viney","year":"2021","unstructured":"Viney L, Burckstummer T, Eddington C, Mietzsch M, Choudhry M, Henley T, et al. Adeno-associated virus (AAV) capsid chimeras with enhanced infectivity reveal a core element in the AAV genome critical for both cell transduction and capsid assembly. J Virol. 2021. https:\/\/doi.org\/10.1128\/jvi.02023-20.","journal-title":"J Virol"},{"key":"1194_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03017-12","author":"E Horowitz","year":"2013","unstructured":"Horowitz E, Rahman S, Bower B, Dismuke D, Falvo M, Griffith J, et al. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol. 2013. https:\/\/doi.org\/10.1128\/jvi.03017-12.","journal-title":"J Virol"},{"key":"1194_CR34","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232369708250327081305","author":"B Hoyle","year":"2025","unstructured":"Hoyle B, Bello D, Hill J, Das S, Kim J. Imaged capillary isoelectric focusing (icIEF) platform for characterization of charge variants of adeno-associated virus (AAV) capsids and impact on their transduction efficiency. Curr Gene Ther. 2025. https:\/\/doi.org\/10.2174\/0115665232369708250327081305.","journal-title":"Curr Gene Ther"},{"key":"1194_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2019.173","volume":"31","author":"L Muraine","year":"2020","unstructured":"Muraine L, Bensalah M, Dhiab J, Cordova G, Arandel L, Marhic A, et al. Transduction Efficiency of Adeno-Associated Virus Serotypes After Local Injection in Mouse and Human Skeletal Muscle. Hum Gene Ther. 2020;31:3\u20134. https:\/\/doi.org\/10.1089\/hum.2019.173.","journal-title":"Hum Gene Ther"},{"key":"1194_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.707607","author":"B Liu","year":"2021","unstructured":"Liu B, Li Z, Huang S, Yan B, He S, Chen F, et al. AAV-containing exosomes as a novel vector for improved gene delivery to lung cancer cells. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.707607.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1194_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2003.09.013","volume":"94","author":"A El-Aneed","year":"2004","unstructured":"El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release. 2004;94(1):1\u201314. https:\/\/doi.org\/10.1016\/j.jconrel.2003.09.013.","journal-title":"J Control Release"},{"key":"1194_CR38","doi-asserted-by":"publisher","unstructured":"Reul J, Frisch J, Engeland C, Thalheimer F, Hartmann J, Ungerechts G, Buccholz C. Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Front. Oncol. 2019;9. https:\/\/doi.org\/10.3389\/fonc.2019.00052.","DOI":"10.3389\/fonc.2019.00052"},{"key":"1194_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/gt.2008.64","volume":"15","author":"I Alexander","year":"2008","unstructured":"Alexander I, Cunningham S, Logan G, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008;15:831\u20139. https:\/\/doi.org\/10.1038\/gt.2008.64.","journal-title":"Gene Ther"},{"issue":"6","key":"1194_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"W Wold","year":"2013","unstructured":"Wold W, Toth K. Adenovirus vectors for gene therapy, vaccination, and cancer gene therapy. Curr Gene Ther. 2013;13(6):421\u201333. https:\/\/doi.org\/10.2174\/1566523213666131125095046.","journal-title":"Curr Gene Ther"},{"issue":"12","key":"1194_CR41","doi-asserted-by":"publisher","first-page":"P2123","DOI":"10.1016\/j.omtm.2019.01.008","volume":"27","author":"H Buning","year":"2019","unstructured":"Buning H, Srivastava A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev. 2019;27(12):P2123-2133. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.008.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"1194_CR42","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1002\/bit.28508","volume":"120","author":"Q Fu","year":"2023","unstructured":"Fu Q, Lee Y, Green E, Wang Y, Park S, Polanco A, et al. Design space determination to optimize DNA complexation and full capsid formation in transient rAAV manufacturing. Biotechnol Bioeng. 2023;120(11):3148\u20134162. https:\/\/doi.org\/10.1002\/bit.28508.","journal-title":"Biotechnol Bioeng"},{"key":"1194_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.omtm.2018.07.004","volume":"10","author":"A Francois","year":"2018","unstructured":"Francois A, Bouzelha M, Lecomte E, Broucque F, Penaud-Budloo M, Adjali O, et al. Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls. Mol Ther Methods Clin Dev. 2018;10:223\u201336. https:\/\/doi.org\/10.1016\/j.omtm.2018.07.004.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"1194_CR44","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1566524020999200730181042","volume":"20","author":"L Hajba","year":"2020","unstructured":"Hajba L, Guttman A. Recent advances in the analysis of full\/empty capsid ratio and genome integrity of adeno-associated virus (AAV) gene delivery vectors. Curr Mol Med. 2020;20(8):806\u201313. https:\/\/doi.org\/10.2174\/1566524020999200730181042.","journal-title":"Curr Mol Med"},{"key":"1194_CR45","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.140","author":"K Chamberlain","year":"2016","unstructured":"Chamberlain K, Riyad J, Weber T. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther. 2016. https:\/\/doi.org\/10.1089\/hgtb.2015.140.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"1194_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-023-00518-5","volume":"21","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Hao G. Biophysical characterization of adeno-associated virus capsid through the viral transduction life cycle. J Genet Eng Biotechnol. 2023;21(1):10.1186\/s43141-023-00518-5.","journal-title":"J Genet Eng Biotechnol"},{"issue":"5","key":"1194_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050750","volume":"13","author":"M Korneyenkov","year":"2021","unstructured":"Korneyenkov M, Zamyatnin A. Next step in gene delivery: modern approaches and further perspectives of AAV tropism modification. Pharmaceutics. 2021;13(5):750. https:\/\/doi.org\/10.3390\/pharmaceutics13050750.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1194_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1566523054064968","volume":"5","author":"V Choi","year":"2005","unstructured":"Choi V, McCarty D, Samulski R. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther. 2005;5(12):299\u2013310. https:\/\/doi.org\/10.2174\/1566523054064968.","journal-title":"Curr Gene Ther"},{"key":"1194_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/gt.2016.75","volume":"24","author":"M Wang","year":"2016","unstructured":"Wang M, Sun J, Woodard K, Hirsch M, Samulski R, Li C. Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications. Gene Ther. 2016;24:49\u201359. https:\/\/doi.org\/10.1038\/gt.2016.75.","journal-title":"Gene Ther"},{"issue":"9","key":"1194_CR50","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","volume":"22","author":"T Kishimoto","year":"2022","unstructured":"Kishimoto T, Samulski R. Addressing high dose AAV toxicity \u2013 \u2018one and done\u2019 or \u2018slower and lower\u2019? Expert Opin Biol Ther. 2022;22(9):1067\u201371. https:\/\/doi.org\/10.1080\/14712598.2022.2060737.","journal-title":"Expert Opin Biol Ther"},{"key":"1194_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00028","author":"E Basner-Tschakarjan","year":"2014","unstructured":"Basner-Tschakarjan E, Bijjiga E, Martino A. Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2014. https:\/\/doi.org\/10.3389\/fimmu.2014.00028.","journal-title":"Front Immunol"},{"issue":"5","key":"1194_CR52","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/156652307782151425","volume":"7","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, High K. Immune responses to AAV in clinical trials. Curr Gene Ther. 2007;7(5):316\u201324. https:\/\/doi.org\/10.2174\/156652307782151425.","journal-title":"Curr Gene Ther"},{"issue":"9-10","key":"1194_CR53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/hum.2019.264","volume":"31","author":"A Westhaus","year":"2020","unstructured":"Westhaus A, Cabanes-Creus M, Rybicki A, Baltazar G, Navarro R, Zhu R, et al. High-throughput in vitro, ex vivo, and in vivo screen of adeno-associated virus vectors based on physical and functional transduction. Hum Gene Ther. 2020;31(9\u201310):575\u201389. https:\/\/doi.org\/10.1089\/hum.2019.264.","journal-title":"Hum Gene Ther"},{"issue":"194","key":"1194_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005795","volume":"5","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, Anguela Z, Pavani G, Chen Y, Davidson R, Hui D, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013;5(194):194ra92. https:\/\/doi.org\/10.1126\/scitranslmed.3005795.","journal-title":"Sci Transl Med"},{"key":"1194_CR55","doi-asserted-by":"publisher","unstructured":"Aalbers C, Broesktra N, van Geldorp M, Kramer E, Ramiro S, Tak P, Vervoordeldonk M, Finn J Empty Capsids and Macrophage Inhibition\/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice. Human Gene Therapy 2017;28:2, https:\/\/doi.org\/10.1089\/hum.2016.036.","DOI":"10.1089\/hum.2016.036"},{"key":"1194_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78521-w","volume":"10","author":"M Davidsson","year":"2020","unstructured":"Davidsson M, Negrini M, Hauser S, Svanbergsson A, Lockowandt M, Tomasello G, et al. A comparison of AAV-vector production methods for gene therapy and preclinical assessment. Sci Rep. 2020;10:21532. https:\/\/doi.org\/10.1038\/s41598-020-78521-w.","journal-title":"Sci Rep"},{"key":"1194_CR57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2018.04.005","volume":"9","author":"L Lieshout","year":"2018","unstructured":"Lieshout L, Domm J, Rindler T, Frost K, Sorensen D, Medina S, et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Molecular Therapy Methods & Clinical Development. 2018;9:323\u20139. https:\/\/doi.org\/10.1016\/j.omtm.2018.04.005.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"1194_CR58","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/sj.gt.3302611","volume":"1","author":"E Burova","year":"2005","unstructured":"Burova E, Loffe E. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther. 2005;1:S5-17. https:\/\/doi.org\/10.1038\/sj.gt.3302611.","journal-title":"Gene Ther"},{"key":"1194_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.apcsb.2023.11.013","volume":"139","author":"S Singh","year":"2024","unstructured":"Singh S, Pandey A, Malemnganba T, Prajapati V. Chapter three \u2013 technological advancements in viral vector designing and optimization for therapeutic applications. Adv Protein Chem Struct Biol. 2024;139:57\u201387. https:\/\/doi.org\/10.1016\/bs.apcsb.2023.11.013.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"1194_CR60","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.omtm.2023.05.004","volume":"29","author":"L Van Lieshout","year":"2023","unstructured":"Van Lieshout L, Rubin M, Costa-Grant K, Ota S, Golebiowski D, Panico T, et al. A novel dual-plasmid platform provides scalable transfection yielding improved productivity and packaging across multiple AAV serotypes and genomes. Mol Ther Methods Clin Dev. 2023;29:426\u201336. https:\/\/doi.org\/10.1016\/j.omtm.2023.05.004.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"1194_CR61","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/mt.2015.206","volume":"23","author":"M Kay","year":"2015","unstructured":"Kay M. Selecting the Best AAV Capsid for Human Studies. Mol Ther. 2015;23(12):1800\u20131. https:\/\/doi.org\/10.1038\/mt.2015.206.","journal-title":"Mol Ther"},{"key":"1194_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2023.03.002","volume":"29","author":"X He","year":"2023","unstructured":"He X, Powers T, Huang S, Liu Z, Shi H, Orlet J, et al. Development of an icIEF assay for monitoring AAV capsid proteins and application to gene therapy products. Molecular Therapy Methods & Clinical Development. 2023;29:133\u201344. https:\/\/doi.org\/10.1016\/j.omtm.2023.03.002.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"12","key":"1194_CR63","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1016\/j.ymthe.2018.09.013","volume":"26","author":"A Giles","year":"2018","unstructured":"Giles A, Sims J, Turner K, Govindasamy L, Alvira M, Lock M, et al. Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered function. Mol Ther. 2018;26(12):2848\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.013.","journal-title":"Mol Ther"},{"key":"1194_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2023.115099","volume":"668","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang Y. Direct deamidation analysis of intact adeno-associated virus serotype 9 capsid proteins using reversed-phase liquid chromatography. Anal Biochem. 2023;668:115099. https:\/\/doi.org\/10.1016\/j.ab.2023.115099.","journal-title":"Anal Biochem"},{"key":"1194_CR65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","volume":"18","author":"N Rumachik","year":"2020","unstructured":"Rumachik N, Malaker S, Poweleit N, Maynard L, Adams C, Leib R, et al. Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Molecular Therapy Methods & Clinical Development. 2020;18:98\u2013118. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.018.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"1194_CR66","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2147\/DDDT.S80496","volume":"10","author":"V Osamor","year":"2016","unstructured":"Osamor V, Chinedu S, Azuh D, Iweala E, Ogunlana O. The interplay of post-translational modification and gene therapy. Drug Des Devel Ther. 2016;10:861\u201371. https:\/\/doi.org\/10.2147\/DDDT.S80496.","journal-title":"Drug Des Devel Ther"},{"key":"1194_CR67","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.omtm.2022.10.008","volume":"27","author":"L Barnes","year":"2022","unstructured":"Barnes L, Draper B, Jarrold M. Analysis of thermally driven structural changes, genome release, disassembly, and aggregation of recombinant AAV by CDMS. Mol Ther Methods Clin Dev. 2022;27:327\u201336. https:\/\/doi.org\/10.1016\/j.omtm.2022.10.008.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1194_CR68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.omtm.2020.06.005","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Guo P, Zhang J, Chrzanowski M, Chew H, Firrman J, et al. Effects of thermally induced configuration changes on rAAV genome\u2019s enzymatic accessibility. Mol Ther Methods Clin Dev. 2020;18:328\u201334. https:\/\/doi.org\/10.1016\/j.omtm.2020.06.005.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"1194_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101293","volume":"32","author":"E Ebberink","year":"2024","unstructured":"Ebberink E, Ruisinger A, Nuebel M, Meyer-Berg H, Ferreira I, Thomann M, et al. Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry. Mol Ther Methods Clin Dev. 2024;32(3):101293. https:\/\/doi.org\/10.1016\/j.omtm.2024.101293.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1194_CR70","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.124","author":"A Lam","year":"2021","unstructured":"Lam A, Frabutt D, Li L, Xiao W. Chemical modifications of the capsid for redirecting and improving the efficacy of adeno-associated virus vectors. Hum Gene Ther. 2021. https:\/\/doi.org\/10.1089\/hum.2021.124.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"1194_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","volume":"14","author":"J Forsayeth","year":"2006","unstructured":"Forsayeth J, Eberling J, Sanftner L, Zhen Z, Pivirotto P, Bringas J, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther. 2006;14(4):571\u20137. https:\/\/doi.org\/10.1016\/j.ymthe.2006.04.008.","journal-title":"Mol Ther"},{"key":"1194_CR72","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.069","author":"A Maurer","year":"2020","unstructured":"Maurer A, Weitzman M. Adeno-associated virus genome interactions important for vector production and transduction. Hum Gene Ther. 2020. https:\/\/doi.org\/10.1089\/hum.2020.069.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"1194_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.cir.0000109697.68832.5d","volume":"109","author":"S White","year":"2004","unstructured":"White S, Nicklin S, Buning H, Brosnan M, Leike K, Papadakis E, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109(4):513\u20139. https:\/\/doi.org\/10.1161\/01.cir.0000109697.68832.5d.","journal-title":"Circulation"},{"issue":"4","key":"1194_CR74","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/mt.2009.135","volume":"10","author":"M Blankinship","year":"2004","unstructured":"Blankinship M, Gregorevic P, Allen J, Harper S, Harper H, Halbert C, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 2004;10(4):671\u20138. https:\/\/doi.org\/10.1038\/mt.2009.135.","journal-title":"Mol Ther"},{"issue":"5","key":"1194_CR75","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/etls20210179","volume":"5","author":"T Hitchcock","year":"2021","unstructured":"Hitchcock T. Manufacturing of AAV vectors: translational challenges from development to industrialization. Emerg Top Life Sci. 2021;5(5):725\u20138. https:\/\/doi.org\/10.1042\/etls20210179.","journal-title":"Emerg Top Life Sci"},{"issue":"1","key":"1194_CR76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virol.2011.08.011","volume":"420","author":"Q Xie","year":"2011","unstructured":"Xie Q, Lerch T, Meyer N, Chapman M. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology. 2011;420(1):10\u20139. https:\/\/doi.org\/10.1016\/j.virol.2011.08.011.","journal-title":"Virology"},{"key":"1194_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jbiotec.2024.12.007","volume":"398","author":"A Maccani","year":"2025","unstructured":"Maccani A, Pachlinger R, Eisenhut P, Unterthurner S, Heider S, Repik C, et al. Potency by design: novel insights in transfection and purification for manufacturing of rAAV gene therapy vectors. J Biotechnol. 2025;398:127\u201332. https:\/\/doi.org\/10.1016\/j.jbiotec.2024.12.007.","journal-title":"J Biotechnol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01194-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:21:00Z","timestamp":1770826860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01194-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01194-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brandon Hoyle and Jonathan Hill\u00a0are employed by Solid Biosciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"36"}}